keyword
MENU ▼
Read by QxMD icon Read
search

sirolimus

keyword
https://www.readbyqxmd.com/read/29467937/temozolomide-sirolimus-and-chloroquine-is-a-new-therapeutic-combination-that-synergizes-to-disrupt-lysosomal-function-and-cholesterol-homeostasis-in-gbm-cells
#1
Sanford P C Hsu, John S Kuo, Hsin-Chien Chiang, Hsin-Ell Wang, Yu-Shan Wang, Cheng-Chung Huang, Yi-Chun Huang, Mau-Shin Chi, Minesh P Mehta, Kwan-Hwa Chi
Glioblastoma (GBM) cells are characterized by high phagocytosis, lipogenesis, exocytosis activities, low autophagy capacity and high lysosomal demand are necessary for survival and invasion. The lysosome stands at the cross roads of lipid biosynthesis, transporting, sorting between exogenous and endogenous cholesterol. We hypothesized that three already approved drugs, the autophagy inducer, sirolimus (rapamycin, Rapa), the autophagy inhibitor, chloroquine (CQ), and DNA alkylating chemotherapy, temozolomide (TMZ) could synergize against GBM...
January 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29465551/sirolimus-alternative-to-blood-transfusion-as-a-life-saver-in-blue-rubber-bleb-nevus-syndrome-a-case-report
#2
Ke-Ling Wang, Shu-Fang Ma, Ling-Yu Pang, Meng-Na Zhang, Lin-Yan Hu, Meng-Jia Liu, Li-Ping Zou
RATIONALE: Blue rubber bleb nevus syndrome (BRBNS) is a rare disease characterized by multiple venous malformations. The gastrointestinal bleeding and secondary iron deficiency anemia are the most common complications. There are currently no effective treatments for BRBNS. Here, we report a case of successful treatment with a small dose of sirolimus of a BRBN patient with a de novo gene mutation. PATIENT CONCERNS: A 12-year-old female was admitted to our hospital with multiple hemangiomas for 12 years...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29458386/functional-improvements-in-patients-with-lymphangioleiomyomatosis-after-sirolimus-an-observational-study
#3
Yongzhong Zhan, Lisha Shen, Wenshuai Xu, Xiuxiu Wu, Weihong Zhang, Jun Wang, Xue Li, Yanli Yang, Xinlun Tian, Kai-Feng Xu
BACKGROUND: Sirolimus has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). We wish to summarize our experience using sirolimus and its effectiveness in LAM patients. METHODS: We analyzed data from 98 patients who were diagnosed with definite or probable sporadic LAM based on the European Respiratory Society diagnosis criteria for LAM in 2010 at Peking Union Medical College Hospital and who had received sirolimus during January 2007 to June 2015...
February 20, 2018: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/29458247/magic-touch-preliminary-clinical-evidence-with-a-novel-sirolimus-drug-coated-balloon
#4
Bernardo Cortese, Gaetano DI Palma, Roberto Latini
Drug-coated balloons (DCB) have been developed in recent years to overcome some of the DES limitations. There is an established indication for the use of DCB in the treatment of in-stent restenosis and they are also variably used in various setting, in particular small coronary vessels and bifurcations. Until 2016, all DCBs available in Europe eluted paclitaxel, a highly lipophilic drug with narrow therapeutic window. In April 2016 a new sirolimus-coated balloon (SCB, Magic Touch®, Envision Scientific PVT, India), obtained the CE Mark...
February 19, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29454679/the-prevalence-and-etiology-of-extreme-hypertriglyceridemia-in-children-data-from-a-tertiary-children-s-hospital
#5
Nivedita Patni, Xilong Li, Beverley Adams-Huet, Abhimanyu Garg
BACKGROUND: Extreme hypertriglyceridemia (eHTG; serum triglycerides ≥ 2000 mg/dL) poses a significant risk for acute pancreatitis. There is paucity of data regarding the prevalence and etiology of eHTG in children. OBJECTIVE: To determine the prevalence, clinical features and etiologies of patients with eHTG at a tertiary children's hospital in the United States and in the United States National Health and Nutrition Examination Survey (NHANES). METHODS: A retrospective analysis was conducted of the electronic medical records of the Children's Medical Center, Dallas, from 2000-2015, and the NHANES data from 2005-2014 for eHTG...
January 12, 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29447818/sirolimus-for-management-of-complex-vascular-anomalies-a-proposed-dosing-regimen-for-very-young-infants
#6
Josephine A Czechowicz, Janel R Long-Boyle, Kristina W Rosbe, Erin F Mathes, Ilona J Frieden, Kristin A Shimano
Neonates with vascular anomalies causing airway compromise and other complications require early initiation of medical therapy. Sirolimus has emerged as a safe and effective treatment, but standard recommendations for dosing start at seven months. Guidelines are needed for dosing in very young infants, who have reduced hepatic metabolism of sirolimus. We present our experience treating six neonates (mean age 14.8 days) with complicated vascular anomalies. Standard dosing caused supratherapeutic levels in this population...
February 2018: International Journal of Pediatric Otorhinolaryngology
https://www.readbyqxmd.com/read/29447787/rationale-and-design-of-the-comparison-between-a-p2y12-inhibitor-monotherapy-versus-dual-antiplatelet-therapy-in-patients-undergoing-implantation-of-coronary-drug-eluting-stents-smart-choice-a-prospective-multicenter-randomized-trial
#7
Young Bin Song, Seok Kyu Oh, Ju-Hyeon Oh, Eul-Soon Im, Deok-Kyu Cho, Byung Ryul Cho, Jong-Young Lee, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuck Choi, Sang Hoon Lee, Hyeon-Cheol Gwon, Joo-Yong Hahn
BACKGROUND AND RATIONALE: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. It is unclear whether P2Y12 inhibitor monotherapy might maintain anti-ischemic efficacy while reducing the bleeding risk compared with DAPT after implantation of the current generation of drug-eluting stents (DES)...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29444470/effect-of-sirolimus-on-liver-cirrhosis-and-hepatic-encephalopathy-of-common-bile-duct-ligated-rats
#8
Kuo-Cheng Wu, Hui-Chun Huang, Ting Chang, Wen-Shin Lee, Chiao-Lin Chuang, I-Fang Hsin, Shao-Jung Hsu, Fa-Yauh Lee, Ching-Chih Chang, Shou-Dong Lee
Cirrhosis is often associated with portal hypertension and portal-systemic collateral vessels formation attributed to angiogenesis, which leads to severe complications as hepatic encephalopathy. Sirolimus has anti-fibrosis and anti-angiogenesis effects, but whether it influences the severity of portal-systemic collaterals and hepatic encephalopathy is unknown. This study was thus designed to address this issue in rats with common bile duct ligation-induced liver cirrhosis. Sham-operated rats were surgical controls...
February 11, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29440231/-ex-vivo-activity-of-cytotoxic-drugs-and-targeted-agents-in-small-intestinal-nets
#9
Kosmas Daskalakis, Olov Norlen, Andreas Karakatsanis, Per Hellman, Rolf Larsson, Peter Nygren, Peter Stalberg
Small intestinal endocrine tumours (SI-NETs) are generally considered resistant to systemic treatment. To date, predictive markers for drug activity are lacking. Tumour samples from 27 patients with SI-NETs were analyzed ex vivo for sensitivity to a panel of cytotoxic drugs and targeted agents using a short-term total cell kill assay. Samples of renal cancer, colorectal cancer (CRC), ovarian cancer, and chronic lymphocytic leukemia (CLL) were included for comparison. For the SI-NET subset, drug sensitivity was analyzed in relation to clinico-pathological variables and pre-treatment biomarkers...
February 12, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29427352/a-rare-case-of-epstein-barr-virus-associated-hepatosplenic-smooth-muscle-tumors-after-kidney-transplantation
#10
Christoph Pircher, Stefan Schneeberger, Claudia Boesmueller, Abbas Agaimy, Heinz Zoller, Reto Bale, Benjamin Henninger, Gert Mayer, Hannes Neuwirt
A 27-year old caucasian male was diagnosed 2.7 years after kidney transplantation with Epstein-Barr virus (EBV)-associated smooth muscle tumors in liver and spleen. The reduction of immunosuppression and conversion from tacrolimus to sirolimus did not lead to a regression of the tumors. Additionally, the patient developed a cellular rejection of his renal allograft, which was successfully treated. A combined approach with stereotactic radiofrequency ablation (SRFA) and surgical resection was effective in the treatment of the tumors...
February 10, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29426631/outcomes-of-a-novel-thin-strut-bioresorbable-polymer-sirolimus-eluting-stent-in-patients-with-chronic-total-occlusions-a-multicenter-registry
#11
Lorenzo Azzalini, Ozan M Demir, Gabriele L Gasparini, Luca Grancini, Alessio La Manna, Soledad Ojeda, Susanna Benincasa, Barbara Bellini, Enrico Poletti, Davide Maccagni, Margherita Soldi, Loredana Iannetta, Daniela Trabattoni, Giacomo Gravina, Francisco Hidalgo, Francesco Giannini, Manuel Pan, Corrado Tamburino, Antonio L Bartorelli, Bernhard Reimers, Cosmo Godino, Mauro Carlino, Antonio Colombo
BACKGROUND: We aimed to evaluate the mid-term outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI), as compared with durable-polymer everolimus-eluting stents (EES). METHODS: We compiled a multicenter registry of patients undergoing CTO recanalization followed by BP-SES or EES implantation. The primary endpoint was the incidence of target-lesion failure (TLF, a composite of cardiac death, target-vessel myocardial infarction, and target-lesion revascularization) at one year...
January 31, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29421608/defining-drug-and-target-protein-distributions-after-stent-based-drug-release-durable-versus-deployable-coatings
#12
Abraham R Tzafriri, Fernando Garcia-Polite, Xiaojian Li, John Keating, Josep-Maria Balaguer, Brett Zani, Lynn Bailey, Peter Markham, Timothy C Kiorpes, Wenda Carlyle, Elazer R Edelman
BACKGROUND: Innovations in drug eluting stent designs make it increasingly important to develop models for differentiating performance through spatial definition of drug, receptor binding and cell state. METHODS: Two designs of sirolimus analog eluting stents were implanted into porcine coronary arteries for 28, 60 or 90 days (n = 9/time point), durable coating (Xience) and deployable absorbable coating (MiStent). Explanted arteries were evaluated for drug content (n = 3/time point) by LC-MS/MS and for drug and target protein (mTOR) distributions by immunofluorescence (IF, n = 6/time point)...
February 5, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29420960/long-term-sirolimus-for-primary-immunosuppression-in-heart-transplant-recipients
#13
Rabea Asleh, Alexandros Briasoulis, Walter K Kremers, Rosalyn Adigun, Barry A Boilson, Naveen L Pereira, Brooks S Edwards, Alfredo L Clavell, John A Schirger, Richard J Rodeheffer, Robert P Frantz, Lyle D Joyce, Simon Maltais, John M Stulak, Richard C Daly, Jonella Tilford, Woong-Gil Choi, Amir Lerman, Sudhir S Kushwaha
BACKGROUND: Small studies have reported superiority of sirolimus (SRL) over calcineurin inhibitor (CNI) in mitigating cardiac allograft vasculopathy (CAV) after heart transplantation (HT). However, data on the long-term effect on CAV progression and clinical outcomes are lacking. OBJECTIVES: The aim of this study was to test the long-term safety and efficacy of conversion from CNI to SRL as maintenance therapy on CAV progression and outcomes after HT. METHODS: A cohort of 402 patients who underwent HT and were either treated with CNI alone (n = 134) or converted from CNI to SRL (n = 268) as primary immunosuppression was analyzed...
February 13, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29413240/a-randomized-trial-comparing-the-neovas-sirolimus-eluting-bioresorbable-scaffold-and-metallic-everolimus-eluting-stents
#14
Yaling Han, Bo Xu, Guosheng Fu, Xiaozeng Wang, Kai Xu, Chongying Jin, Ling Tao, Lang Li, Yuqing Hou, Xi Su, Quan Fang, Lianglong Chen, Huiliang Liu, Bin Wang, Zuyi Yuan, Chuanyu Gao, Shenghua Zhou, Zhongwei Sun, Yanyan Zhao, Changdong Guan, Gregg W Stone
OBJECTIVES: The authors sought to evaluate the safety and effectiveness of the NeoVas bioresorbable scaffold (BRS) compared with metallic drug-eluting stents. BACKGROUND: BRS have the potential to improve very late outcomes compared with metallic drug-eluting stents, but some BRS have been associated with increased rates of device thrombosis before complete bioresorption. NeoVas is a new poly-l-lactic acid BRS that elutes sirolimus from a poly-D, l-lactide coating...
February 12, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29411523/first-report-of-the-use-of-long-tapered-sirolimus-eluting-coronary-stent-for-the-treatment-of-chronic-total-occlusions-with-the-hybrid-algorithm
#15
Carlo Zivelonghi, Jan P van Kuijk, Vincent Nijenhuis, Enrico Poletti, Maarten J Suttorp, Jan A S van der Heyden, Frank D Eefting, Benno J Rensing, Jurrien M Ten Berg, Lorenzo Azzalini, Floris S van den Brink, Flavio Ribichini, Antonio Colombo, José P S Henriques, Pierfrancesco Agostoni
BACKGROUND: Coronary chronic total occlusions (CTO) usually coexist with diffusely diseased coronary segments proximal and/or distal to the CTO segment. During percutaneous treatment of CTO, multiple overlapping stents are often needed to treat these long lesions. OBJECTIVES: Aim of this study is to report the first use of long, tapered coronary sirolimus-eluting stents (SES) in this setting. METHODS AND RESULTS: This is a retrospective analysis of 100 consecutive patients undergoing CTO recanalization following the hybrid algorithm...
February 7, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29407180/allogeneic-hematopoietic-cell-transplantation-in-t-cell-prolymphocytic-leukemia-a-single-center-experience
#16
Bhagirathbhai R Dholaria, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori, Julio C Chavez, Mohammad Hussaini, Ambuj Kumar, Mohamed A Kharfan-Dabaja
BACKGROUND: T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and improve survival, but data is limited. PATIENTS AND METHODS: We evaluated clinical outcomes of 11 patients, median age of 56 (range, 43-71) years who underwent allo-HCT for T-PLL...
January 29, 2018: Leukemia Research
https://www.readbyqxmd.com/read/29405800/sirolimus-induced-regression-of-a-large-orbital-lymphangioma
#17
Wolf A Lagrèze, Lutz Joachimsen, Nikolai Gross, Christian Taschner, Jochen Rössler
Microcystic lymphatic malformations are difficult to treat surgically, especially when located in the orbital apex. Recently, pharmacologic inhibition of the mTOR pathway by sirolimus was reported as a safe and efficacious treatment option for lymphatic malformations (also known as lymphangiomas). We report the case of a young male patient in which a unilateral, retrobulbar lymphatic malformation regressed to a large extent under treatment with 1 mg sirolimus given orally twice a day over a period of six months...
February 6, 2018: Orbit
https://www.readbyqxmd.com/read/29403023/allogenic-peripheral-stem-cell-transplantation-from-hla-matched-related-donors-for-adult-sickle-cell-disease-remarkable-outcomes-from-a-single-center-trial
#18
H Ozdogu, C Boga, M Yeral, I Kozanoglu, C Gereklioglu, P Aytan, M Kasar, S Asma, N Buyukkurt, S Solmaz, A Korur, C Sariturk
Adult patients with sickle cell disease (SCD) are highly susceptible to stem cell transplant complications, including drug toxicity, graft versus host disease (GVHD), and graft rejection due to SCD-related tissue damage, endothelial activation, and inflammation. The scarcity of compatible stem cells for transplantation further limits treatment options, with only 43 cases of adult allogeneic peripheral blood stem cell transplantation (allo-PSCT) from human leukocyte antigen (HLA)-identical sibling donors reported in the international registry for the period 1986-2013...
February 5, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29400652/comparison-between-two-biodegradable-polymer-based-sirolimus-eluting-stents-with-differing-drug-elution-and-polymer-absorption-kinetics-two-year-clinical-outcomes-of-the-panda-iii-trial
#19
Juan Wang, Changdong Guan, Shubin Qiao, Xuebin Cao, Lei Qin, Yi Li, Zhanquan Li, Xueqi Li, Jiansong Yuan, Runlin Gao, Bo Xu
AIMS: In PANDA III trial, the novel poly-lactide-co-glycolide polymer-based BuMA sirolimus-eluting stent (SES) was non-inferior to the polylactide polymer-based Excel SES for the primary endpoint of 1-year target lesion failure (TLF), with a lower incidence of stent thrombosis. We sought to investigate whether the effectiveness profile of BuMA SES, with more rapid drug elution and polymer absorption kinetics, would persist at 2 years. METHODS AND RESULTS: A total of 2,348 patients (mean age, 61...
February 6, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29392879/one-year-clinical-outcomes-and-multislice-computed-tomography-angiographic-results-following-implantation-of-the-neovas-bioresorbable-sirolimus-eluting-scaffold-in-patients-with-single-de-novo-coronary-artery-lesions
#20
Xiao-Zeng Wang, Yao-Jun Zhang, Guo-Sheng Fu, Quan-Min Jing, Bo Xu, Ya-Ling Han
BACKGROUND: Tremendous efforts have been made to establish the concept of vascular restoration therapy with a fully bioresorbable scaffold for coronary artery disease. With an improved scaffold design and technologies, the novel NeoVas scaffold has shown promising clinical performance at 6 months follow-up. OBJECTIVE: The aim of this study was to investigate the 1 year clinical outcomes and multislice computed tomography (MSCT) angiographic results after implantation of the NeoVas scaffold in patients with single de novo coronary artery lesions...
February 2, 2018: Catheterization and Cardiovascular Interventions
keyword
keyword
4707
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"